<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Electrocore Llc — News on 6ix</title>
<link>https://6ix.com/company/electrocore-llc</link>
<description>Latest news and press releases for Electrocore Llc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/electrocore-llc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835614778dffbe2df0ee5ab.webp</url>
<title>Electrocore Llc</title>
<link>https://6ix.com/company/electrocore-llc</link>
</image>
<item>
<title>electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-product-line-featured-in-documentary-underscoring-the-expanding-clinical-and-commercial-role-of-vagus-nerve-stimulation</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-product-line-featured-in-documentary-underscoring-the-expanding-clinical-and-commercial-role-of-vagus-nerve-stimulation</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced its participation in Hacking the Vagus Nerve, a documentary from the Healing Journeys series produced by The Root Cause Project and The Vagus Nerve Society. The film explores the role of the vagus nerve in regulating stress, mood, and immune function and features expert commentary from Peter S. Staats, MD, MBA, Chief Medical Officer</description>
</item>
<item>
<title>electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026. Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day. DATE: April 15, 2026TIME: 2:15 pm ET Investors att</description>
</item>
<item>
<title>electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gammacoretm-nvns-for-ptsd</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gammacoretm-nvns-for-ptsd</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced</description>
</item>
<item>
<title>electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-publication-in-frontiers-in-neuroscience-highlighting-benefits-of-non-invasive-vagus-nerve-stimulation-in-patients-with-mild-traumatic-brain-injury-and-ptsd</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-publication-in-frontiers-in-neuroscience-highlighting-benefits-of-non-invasive-vagus-nerve-stimulation-in-patients-with-mild-traumatic-brain-injury-and-ptsd</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced</description>
</item>
<item>
<title>electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness</description>
</item>
<item>
<title>electroCore Announces Full Year 2025 Financial Results and Organizational Changes</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-full-year-2025-financial-results-and-organizational-changes</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-full-year-2025-financial-results-and-organizational-changes</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription</description>
</item>
<item>
<title>electroCore to Participate at the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-to-participate-at-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-to-participate-at-the-38th-annual-roth-conference</guid>
<pubDate>Tue, 10 Mar 2026 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth</description>
</item>
<item>
<title>electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-to-announce-fourth-quarter-and-full-year-ended-december-31-2025-financial-results-on-thursday-march-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-to-announce-fourth-quarter-and-full-year-ended-december-31-2025-financial-results-on-thursday-march-19-2026</guid>
<pubDate>Mon, 09 Mar 2026 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, March 19</description>
</item>
<item>
<title>Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)</title>
<link>https://6ix.com/company/electrocore-llc/news/acacia-clinics-vagus-nerve-society-130000371</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/acacia-clinics-vagus-nerve-society-130000371</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore’s non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled “Non-Invasive Vagus Nerve Stimulation (nV</description>
</item>
<item>
<title>electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-provides-preliminary-full-2025-130000370</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-provides-preliminary-full-2025-130000370</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today pr</description>
</item>
<item>
<title>TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen</title>
<link>https://6ix.com/company/electrocore-llc/news/tac-stim-demonstrates-significant-performance-130000860</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/tac-stim-demonstrates-significant-performance-130000860</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper presents result</description>
</item>
<item>
<title>electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-participate-canaccord-genuity-medtech-210500396</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-participate-canaccord-genuity-medtech-210500396</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a meeting should</description>
</item>
<item>
<title>electroCore Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-third-quarter-2025-210500484</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-third-quarter-2025-210500484</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025 Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today a</description>
</item>
<item>
<title>electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announce-third-quarter-september-121100255</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announce-third-quarter-september-121100255</guid>
<pubDate>Thu, 23 Oct 2025 12:11:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, November 5, 4:30 PM</description>
</item>
<item>
<title>electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-inducement-grant-under-200500068</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-inducement-grant-under-200500068</guid>
<pubDate>Fri, 03 Oct 2025 20:05:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employ</description>
</item>
<item>
<title>gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms</title>
<link>https://6ix.com/company/electrocore-llc/news/gammacore-non-invasive-vagus-nerve-120000812</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/gammacore-non-invasive-vagus-nerve-120000812</guid>
<pubDate>Tue, 30 Sep 2025 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 million emergency department visits each year in the United</description>
</item>
<item>
<title>electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-reimbursement-approval-gammacore-120000335</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-reimbursement-approval-gammacore-120000335</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on str</description>
</item>
<item>
<title>electroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-truvaga-plus-named-best-120000526</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-truvaga-plus-named-best-120000526</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its Truvaga™ Plus handheld vagus nerve stimulation (nVNS) device has been named the “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards. The annual Sleep Awards from Esquire recognize the most effective and innovative solutions for improving rest and recovery. Truvaga Plus was selected by the magazine’s editors after extensi</description>
</item>
<item>
<title>electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-announces-departure-peter-cuneo-120000120</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-announces-departure-peter-cuneo-120000120</guid>
<pubDate>Fri, 05 Sep 2025 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. “I want to offer my gratitude, and my congratulations to Peter Cuneo on his retirement from</description>
</item>
<item>
<title>electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief</title>
<link>https://6ix.com/company/electrocore-llc/news/electrocore-partners-iheartradio-former-york-120000003</link>
<guid isPermaLink="true">https://6ix.com/company/electrocore-llc/news/electrocore-partners-iheartradio-former-york-120000003</guid>
<pubDate>Thu, 04 Sep 2025 12:00:00 GMT</pubDate>
<description>ROCKAWAY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its partnership with Greg Buttle, former New York Jets linebacker and NFL star, to help raise awareness of Truvaga™ Plus, the Company’s next-generation handheld vagus nerve stimulation (nVNS) device designed to promote calm, clarity, and better sleep. As a standout NFL player and respected sports broadcaster, Mr. Buttle knows firstha</description>
</item>
</channel>
</rss>